N/A N=38 Mobile Sleep Intervention for OEF, OIF and OND Veterans
Chronic Insomnia
Primary: Number of Participants Using WatchPAT — 11; 11 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=110 Effect of Statin Therapy on Disease Progression in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Polycystic Kidney, Autosomal Dominant
Primary: Percent of Participants Demonstrating 20% or More Increase in Total Kidney Volume — 69; 88 percentage of participants — p=0.03
Phase 3 N=1,082 Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as add-on to Metformin With or Without Sulphonylurea in Insulin-naïve Subjects With Type 2 Diabetes
Diabetes · Diabetes Mellitus, Type 2
Primary: Change in HbA1c From Baseline — -1.21; -1.64; -0.83 percentage — p=<0.0001
N/A N=74 Using Non-Fluoroscopic Imaging Devices to Decrease Radiation Exposure During Ablation of Supraventricular Tachycardia
Supraventricular Tachycardia
Primary: Total Fluoroscopy Time — 18.3; 7.5 minutes
Phase 3 N=386 Refractory Overactive Bladder: Sacral NEuromodulation v. BoTulinum Toxin Assessment (ROSETTA)
Urinary Incontinence, Urge
Primary: Number of Urge Urinary Incontinence (UUI) Episodes — -3.25; -3.89 UUI episodes
Phase 2 N=282 A Study of the Efficacy and Safety of EP-101 ( (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease
COPD
Primary: Change From Baseline in Morning Trough Forced Expiratory Volume in 1 Second (FEV1) — 0.0009; 0.1055; 0.1333; 0.1336 liters — p=0.0043
Phase 2 N=119 Study Evaluating Inotuzumab Ozogamicin [CMC-544] Administered In Combination With Rituximab In Subjects With Non-Hodgkin's Lymphoma (NHL)
B-Cell Lymphoma
Primary: Maximum Tolerated Dose (MTD) of Inotuzumab Ozogamicin in Combination With Rituximab (375 mg/m^2 ) — 1.8 mg/m^2
N/A N=72 Outcome Evaluation of Ceramic Crowns Using Two Different Dental Cements
Sensitivity to Dental Cements · Dental Crowns · Dental Three-unit Bridges
Primary: Incidence of Post-operative Pain (Yes/no) — 1; 0; 1; 2 participants — p=0.5637
Phase 3 N=191 Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)
Breast Tumor · Breast Cancer · Cancer of the Breast
Primary: Kaplan-Meier Estimates of Progression-Free Survival (PFS) Based on Investigator Assessment. — 5.5; 8.3; 6.0 months — p=0.0183
Phase 4 N=230 Study Evaluating Subcutaneous Methylnaltrexone For Treatment Of Opioid-Induced Constipation In Patients With Advanced Illness
Opioid-Induced Constipation
Primary: The Proportion of Subjects Who Have a Rescue-free Laxation Response Within 4 Hours After at Least 2 of the First 4 Doses — 62.9; 9.6 percentage of participants — p=<…
N/A N=387 Obalon Balloon System Pivotal IDE (SMART) Trial
Obesity
Primary: Least-Square Mean Difference in % Total Body Loss (TBL) Between the Obalon Treatment and Sham Control Groups — 6.86; 3.59 %TBL — p=0.0261
N/A N=9 Multi-Tracer PET Prediction and Assessment of Response to Gemcitabine in Pancreatic Cancer Patients
Pancreatic Cancer
Primary: FDG Therapeutic Responses to 1 Cycle — 6 participant responses based on EORTC
N/A N=100 Safety Study of Quickclot for Bleeding Control After Adenotonsillectomy
Sleep Apnea, Obstructive
Primary: Total Suction Electrocautery Time Required for Hemostasis Will be Recorded as Seconds — 155.3; 60.9; 94.5 seconds
N/A N=29 Collaborative Research Group for Necrotizing Enterocolitis
Prematurity · Necrotizing Enterocolitis
Primary: Salivary EGF (Epidermal Growth Factor) Protein Levels — 15 picograms EGF/ microgram of protein
Phase 2 N=42 The Fibrin Pad Cardiovascular Study
Cardiovascular Disease
Primary: Hemostasis at the Target Bleeding Site (TBS) at 3 Minutes Following Treatment Application. — 12; 6; 5 Participants